Hillhurst develops technologies enabling the therapeutic use of low-dose carbon monoxide.
Hillhurst Biopharmaceuticals has raised $6.3M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
Hillhurst Biopharmaceuticals's investors include Michael J. Fox Foundation, National Institutes of Health, Friedman BioVentures, National Heart, Lung and Blood Institute, Farmer Family Foundation.
Hillhurst Biopharmaceuticals is headquartered in San Diego, United States.
Hillhurst develops technologies enabling the therapeutic use of low-dose carbon monoxide.
Hillhurst Biopharmaceuticals is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hillhurst Biopharmaceuticals — Funding & Investors." VCBacked, May 8, 2025, https://www.vcbacked.co/company/hillhurst-biopharmaceuticals. Accessed July 19, 2026.
VCBacked. (2025). Hillhurst Biopharmaceuticals — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hillhurst-biopharmaceuticals
{{cite web |title=Hillhurst Biopharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/hillhurst-biopharmaceuticals |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated